ClinicalTrials.gg
Drug

Cladribine clinical trials

Also written Leustatin, 2-CdA, RWJ-26251 and Litak.

studies test it
82
open now
17
in phase 3
17
first study started
1994

How each study uses Cladribine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Cladribine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
26 Feb 1993 · LEUSTATIN · NDA 020229 (FDA, Drugs@FDA)
European Union
14 Apr 2004 · Litak · EMEA/H/C/000504 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cladribine
61
2CDA
16
CdA
15
Cladribina
14
Leustat
14

Brand

Leustatin
27
Litak
2

Development codes

RWJ-26251
14

Other names

2-CdA
24
Mavenclad
13

Studies by the year they started

81 studies that test it; most in 2016 (9); 1 more planned to start later

Studies that test Cladribine, by start year
YearStudies
19941
19961
19971
19983
19991
20022
20032
20045
20052
20061
20086
20093
20101
20111
20122
20142
20169
20171
20186
20193
20206
20218
20226
20232
20241
20253
20262

Who runs them

Industry 10 · Other 72

M.D. Anderson Cancer Center (11) · Fred Hutchinson Cancer Center (5) · University of Washington (5) · Merck KGaA, Darmstadt, Germany (3) · EMD Serono Research & Development Institute, Inc. (3) · Alliance for Clinical Trials in Oncology (3) · Sun Yat-sen University (3) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (2)

Often tested with

Tested in the same studies.

Cytarabine (33) · Mitoxantrone (15) · Rituximab (14) · Venetoclax (8) · Filgrastim (7) · Idarubicin (6) · Granulocyte Colony-Stimulating Factor (5) · Decitabine (5)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Cladribine is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 6, 1 in phase 3

Studies that test Cladribine, phase 3 first.

Studies

Open first, then newest update. How each study uses Cladribine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 82

See all 82 studies that test Cladribine →

Given beside what is tested · 21 — Cladribine is usual care or a partner of the new treatment

Showing 20 of 21.

As the comparator · 4 — what is tested is compared with Cladribine

Codes

What other systems call Cladribine · ClinicalTrials.gg INT008593

  • MeSH (NLM) D017338CladribineConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 47M74X9YT5CLADRIBINEConfirmed FDA, NLM, Wikidata
  • RxNorm 44157Confirmed FDA, Wikidata
  • Wikidata Q414030cladribineConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C1336CladribineConfirmed FDA, Wikidata
  • DrugBank DB00242One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.